Repro Med Net Worth
Repro Med Net Worth Breakdown | KRMD |
Repro Med Net Worth Analysis
Repro Med's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Repro Med's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Repro Med's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Repro Med's net worth analysis. One common approach is to calculate Repro Med's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Repro Med's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Repro Med's net worth. This approach calculates the present value of Repro Med's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Repro Med's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Repro Med's net worth. This involves comparing Repro Med's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Repro Med's net worth relative to its peers.
Enterprise Value |
|
To determine if Repro Med is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Repro Med's net worth research are outlined below:
| Repro Med Systems had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 33.65 M. Net Loss for the year was (6.07 M) with profit before overhead, payroll, taxes, and interest of 23.27 M. | |
| Repro Med Systems currently holds about 18.27 M in cash with (319.72 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: A Look At The Fair Value Of KORU Medical Systems, Inc. |
Repro Med Quarterly Good Will |
|
Repro Med uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Repro Med Systems. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Repro Med's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Repro Med's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Repro Med is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Repro Med Systems backward and forwards among themselves. Repro Med's institutional investor refers to the entity that pools money to purchase Repro Med's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2025-06-30 | 324 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 299.8 K | White Pine Capital Llc | 2025-06-30 | 225.4 K | Acadian Asset Management Llc | 2025-06-30 | 154.3 K | Charles Schwab Investment Management Inc | 2025-06-30 | 119.1 K | Squarepoint Ops Llc | 2025-06-30 | 108.7 K | Renaissance Technologies Corp | 2025-06-30 | 104.6 K | Pnc Financial Services Group Inc | 2025-06-30 | 97 K | Goldman Sachs Group Inc | 2025-06-30 | 90.7 K | First Light Asset Management, Llc | 2025-06-30 | 4.7 M | Topline Capital Management Llc | 2025-06-30 | 3.6 M |
Follow Repro Med's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 183.09 M.Market Cap |
|
Project Repro Med's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.22) | |
| Return On Capital Employed | (0.32) | (0.31) | |
| Return On Assets | (0.22) | (0.21) | |
| Return On Equity | (0.36) | (0.34) |
When accessing Repro Med's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Repro Med's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Repro Med's profitability and make more informed investment decisions.
Please note, the presentation of Repro Med's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Repro Med's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Repro Med's management manipulating its earnings.
Evaluate Repro Med's management efficiency
Repro Med Systems has return on total asset (ROA) of (0.1148) % which means that it has lost $0.1148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2563) %, meaning that it created substantial loss on money invested by shareholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.22. The current year's Return On Capital Employed is expected to grow to -0.31. At present, Repro Med's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 20.1 M, whereas Other Current Assets are forecasted to decline to about 580 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.37 | 0.39 | |
| Tangible Book Value Per Share | 0.35 | 0.37 | |
| Enterprise Value Over EBITDA | (30.72) | (29.19) | |
| Price Book Value Ratio | 10.49 | 11.01 | |
| Enterprise Value Multiple | (30.72) | (29.19) | |
| Price Fair Value | 10.49 | 11.01 | |
| Enterprise Value | 94.6 M | 99.4 M |
Repro Med Systems has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 4.9195 | Revenue | Quarterly Revenue Growth 0.209 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repro Med insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repro Med's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Repro Med insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Repro Med time-series forecasting models is one of many Repro Med's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Repro Med's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Repro Med Earnings per Share Projection vs Actual
Repro Med Corporate Management
| Brian Case | Chief Officer | Profile | |
| Thomas Adams | Chief Officer | Profile | |
| Rob Cannon | Interim Officer | Profile | |
| Josh Bennett | VP Devel | Profile | |
| Kenneth Miller | Chief Officer | Profile | |
| Tom Adams | Interim Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.10) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.